ReviewTransplantation direct2020
Cost-effectiveness of Deceased-donor Renal Transplant Versus Dialysis to Treat End-stage Renal Disease: A Systematic Review.
Review in Transplantation direct, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- A systematic review and quality assessment of economic evaluations of kidney replacement therapies in end-stage kidney disease.Scientific reports · 2024Pooled it
- The xenotransplantation hybrid hospital: structural, economic, and regulatory frameworks for zero-ischemia clinical translation.Clinical transplantation and research · 2026Review
- Educational support programs for individuals with end-stage renal disease on hemodialysis: a scoping review.BMC nephrology · 2026Article
- The Effect of the COVID-19 Pandemic on Diagnostic Testing Time Completion for African American End Stage Renal Disease (ESRD) Patients Being Evaluated for Kidney Transplantation.Journal of racial and ethnic health disparities · 2026Article
- Impact of deceased donor acute kidney injury (AKI) on renal transplant outcomes.Surgery open science · 2026Review
- Simulation of prospective PIRCHE-II molecular matching in Canada: a feasibility study.Frontiers in immunology · 2026Article
- Donor-specific mesenchymal stem cell infusion in human and nonhuman primate kidney transplantation.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2025Article
- Early Steps of the Kidney Transplant Process: What Are the Experiences of Dialysis Social Workers?Clinical transplantation · 2025Article
- 2023 European Kidney Forum: The future of kidney care - investing in green nephrology to meet the European Green Deal targets.Journal of nephrology · 2025Article
- Organ Donation: An Act of Individual Generosity and Civic Solidarity.Transplant international : official journal of the European Society for Organ Transplantation · 2025Article
- Early economic evaluation of chelation therapy in kidney transplant recipients with high-normal lead.PloS one · 2025Article
- Push toward pre-emptive kidney transplantation - for sure?Clinical kidney journal · 2024Review
- Kidney transplantation outcomes: Is it possible to improve when good results are falling down?World journal of transplantation · 2024Article
- BIVARIATE FUNCTIONAL PATTERNS OF LIFETIME MEDICARE COSTS AMONG ESRD PATIENTS.The annals of applied statistics · 2024Article
- Journey to kidney transplantation: patient dynamics, suspensions, transplantation and deaths in the Australian kidney transplant waitlist.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024Article
- Urinary vanin-1, tubular injury, and graft failure in kidney transplant recipients.Scientific reports · 2024Article
- What Genetic Modifications of Source Pigs Are Essential and Sufficient for Cell, Tissue, and Organ Xenotransplantation?Transplant international : official journal of the European Society for Organ Transplantation · 2024Review
- Preventing Rejection of the Kidney Transplant.Journal of clinical medicine · 2023Review
- International Donation and Transplantation Legislative and Policy Forum: Methods and Purpose.Transplantation direct · 2023Article
- Operations Research to Solve Kidney Allocation Problems: A Systematic Review.Healthcare (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Deceased-donor renal transplant (DDRT) is an expensive and potentially risky health intervention with the prospect of improved life and lower long-term costs compared with dialysis. Due to the increasing shortage of kidneys and the associated rise of transplantation costs, certain patient groups may not benefit from transplantation in a cost-effective manner compared with dialysis. The objective of this systematic review was to provide a comprehensive synthesis of evidence on the cost-effectiveness of DDRT relative to dialysis to treat adults with end-stage renal disease and patient-, donor-, and system-level factors that may modify the conclusion. A systematic search of articles was conducted on major databases including MEDLINE, Embase, Scopus, EconLit, and the Health Economic Evaluations Database. Eligible articles were restricted to those published in 2001 or thereafter. Two reviewers independently assessed the suitability of studies and excluded studies that focused on recipients with age <18 years old and those of a living-donor or multiorgan transplant. We show that while DDRT is generally a cost-effective treatment relative to dialysis at conventional willingness-to-pay thresholds, a range of drivers including older patient age, comorbidity, and long wait times significantly reduce the benefit of DDRT while escalating healthcare costs. These findings suggest that the performance of DDRT on older patients with comorbidities should be carefully evaluated to avoid adverse results as evidence suggests that it is not cost-effective. Delayed transplantation may reduce the economic benefits of transplant which necessitates targeted policies that aim to shorten wait times. More recent findings have demonstrated that transplantation using high-risk donors may be a cost-effective and promising alternative to dialysis in the face of a lack of organ availability and fiscal constraints. This review highlights key concepts of health economic evaluations and the relevance of cost-effectiveness to inform care and decision-making in renal programs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.